Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

FRIDAY, Nov. 21, 2025 (HealthDay News) — Pfizer’s mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 ...

Pfizer's mRNA flu vaccine posts promising NEJM results. Dr. Todd Ellerin of South Shore Health discusses safety, side effects ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

A flu vaccine that harnesses the messenger RNA technology that ended the COVID-19 pandemic appears increasingly likely, ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...